Moderna to build mRNA facility in Africa
Company officials predict 500 million vaccine doses per year to be produced via the center, which will offer fill-finish, packaging services
Moderna will be building an mRNA facility in Africa, with the goal of manufacturing up to 500 million doses of vaccines each year at the 50 µg dose level. The biotech company expects to invest up to $500 million into this new facility, which will feature drug substance manufacturing, along with fill-finish and packaging capabilities.
A country and site for the facility are yet to be chosen, but the firm expects to begin the selection process soon.
“ … On behalf of our growing team, partners and shareholders, we are determined to extend Moderna’s societal impact through the investment in a state-of-the-art mRNA manufacturing facility in Africa,” mentions Stéphane Bancel, Moderna’s CEO. “While we are still working to increase capacity in our current network to deliver vaccines for the ongoing pandemic in 2022, we believe it is important to invest in the future. We expect to manufacture our Covid-19 vaccine, as well as additional products within our mRNA vaccine portfolio, at this facility.”
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
